Targovax ASA (GB:0RIS) has released an update.
Circio Holding ASA, a biotech company specializing in RNA therapeutics, has formally called on the Bridge Financing from Atlas Special Opportunities, LLC, by requesting subscription for eight convertible bonds worth NOK 4 million. This move aligns with the terms of their Investment Agreement and aims to support the company until the completion of a planned rights issue intended to raise NOK 52 million. Circio is also advancing in the development of its cancer vaccine TG01, currently in clinical trials for various cancers.
For further insights into GB:0RIS stock, check out TipRanks’ Stock Analysis page.
